Marieke van Son

119 QOL AFTER ULTRAFOCAL SALVAGE HDR-BRACHYTHERAPY 15. Barbera F, Triggiani L, Buglione M, Ghirardelli P, Vitali P, Caraffini B, et al. Salvage Low Dose Rate Brachyther- apy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes. Clin Med Insights Oncol. 2017;11:1179554917738765. 16. Siddiqui KM, Billia M, Arifin A, Li F, Vio- lette P, Chin JL. Pathological, Oncologic and Functional Outcomes of a Prospec- tive Registry of Salvage High Intensity Focused Ultrasound Ablation for Radio- recurrent Prostate Cancer. The Journal of urology. 2017;197(1):97-102. 17. Berge V, Baco E, Dahl AA, Karlsen SJ. Health-related quality of life after sal- vage high-intensity focused ultrasound (HIFU) treatment for locally radiore- current prostate cancer. International journal of urology : official journal of the Japanese Urological Association. 2011;18(9):646-51. 18. Peters M, Maenhout M, van der Voort van Zyp JR, Moerland MA, Moman MR, Steuten LM, et al. Focal salvage iodine- 125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol. 2014;112(1):77-82. 19. Murgic J, Morton G, Loblaw A, D’Ali- monte L, Ravi A, Wronski M, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Fail- ure: Results From a Prospective Clini- cal Trial. Int J Radiat Oncol Biol Phys. 2018;102(3):561-7. 20. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol. 2007;84(2):107-13. 21. Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, et al. Prostate high dose-rate brachytherapy as monothera- py for low and intermediate risk prostate cancer: Efficacy results from a random- ized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Ra- diother Oncol. 2020;146:90-6. 22. Morton G, Chung HT, McGuffin M, Helou J, D’Alimonte L, Ravi A, et al. Pros- tate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. Radio- ther Oncol. 2017;122(1):87-92. 6